RNA Interference Effectors Selectively Silence the Pathogenic Variant GNAO1 c.607 G > A In Vitro
Nucleic Acid Therapeutics · 2024
DOI: 10.1089/nat.2023.0043 ↗Kurz gefasst
Fachartikel in der Zeitschrift Nucleic Acid Therapeutics, 2024. Verfasst von Natalia V Klementieva und 17 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Modeling and Gene Therapy of Hereditary Diseases, Institute of Gene Biology Russian Academy of Sciences, Moscow, Russia. Hauptthemen laut MEDLINE: Genetic Therapy, Brain Diseases. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 46 Literaturangaben.
Abstract (Originalsprache)
RNA interference (RNAi)-based therapeutics hold the potential for dominant genetic disorders, enabling sequence-specific inhibition of pathogenic gene products. We aimed to direct RNAi for the selective suppression of the heterozygous GNAO1 c.607 G > A variant causing GNAO1 encephalopathy. By screening short interfering RNA (siRNA), we showed that GNAO1 c.607G>A is a druggable target for RNAi. The si1488 candidate achieved at least twofold allelic discrimination and downregulated mutant protein to 35%. We created vectorized RNAi by incorporating the si1488 sequence into the short hairpin RNA (shRNA) in the adeno-associated virus (AAV) vector. The shRNA stem and loop were modified to improve the transcription, processing, and guide strand selection. All tested shRNA constructs demonstrated selectivity toward mutant GNAO1 , while tweaking hairpin structure only marginally affected the silencing efficiency. The selectivity of shRNA-mediated silencing was confirmed in the context of AAV vector transduction. To conclude, RNAi effectors ranging from siRNA to AAV-RNAi achieve suppression of the pathogenic GNAO1 c.607G>A and discriminate alleles by the single-nucleotide substitution. For gene therapy development, it is crucial to demonstrate the benefit of these RNAi effectors in patient-specific neurons and animal models of the GNAO1 encephalopathy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratory of Modeling and Gene Therapy of Hereditary Diseases, Institute of Gene Biology Russian Academy of Sciences, Moscow, Russia.
- Marlin Biotech LLC, Sochi, Russia.
- Center for Precision Genome Editing and Genetic Technologies for Biomedicine, Institute of Gene Biology, Russian Academy of Sciences, Moscow, Russia.
- Laboratory of Translational Biomedicine, Gamaleya National Research Center for Epidemiology, Moscow, Russia.
- State Budgetary Healthcare Institution of Moscow Region "Balashikha Hospital," Balashikha, Russia.
- Institute for Regenerative Medicine, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.
ORCID-Profile: Evgenii A Lunev, Maryana V Bardina
Zitieren
APA
Klementieva, N. V., Lunev, E. A., Shmidt, A. A., Loseva, E. M., Savchenko, I. M., Svetlova, E. A., Galkin, I. I., Polikarpova, A. V., Usachev, E. V., Vassilieva, S. G., Marina, V. I., Dzhenkova, M. A., Romanova, A. D., Agutin, A. V., Timakova, A. A., Reshetov, D. A., Egorova, T. V., & Bardina, M. V. (2024). RNA Interference Effectors Selectively Silence the Pathogenic Variant GNAO1 c.607 G > A In Vitro. Nucleic Acid Therapeutics. https://doi.org/10.1089/nat.2023.0043
Vancouver
Klementieva NV, Lunev EA, Shmidt AA, Loseva EM, Savchenko IM, Svetlova EA, et al. RNA Interference Effectors Selectively Silence the Pathogenic Variant GNAO1 c.607 G > A In Vitro. Nucleic Acid Therapeutics. 2024. doi:10.1089/nat.2023.0043
BibTeX
@article{Klementieva2024,
author = {Klementieva, Natalia V and Lunev, Evgenii A and Shmidt, Anna A and Loseva, Elizaveta M and Savchenko, Irina M and Svetlova, Ekaterina A and Galkin, Ivan I and Polikarpova, Anna V and Usachev, Evgeny V and Vassilieva, Svetlana G and Marina, Valeria I and Dzhenkova, Marina A and Romanova, Anna D and Agutin, Anton V and Timakova, Anna A and Reshetov, Denis A and Egorova, Tatiana V and Bardina, Maryana V},
title = {RNA Interference Effectors Selectively Silence the Pathogenic Variant GNAO1 c.607 G > A In Vitro},
journal = {Nucleic Acid Therapeutics},
year = {2024},
doi = {10.1089/nat.2023.0043}
}
EUVIMED